Synapse - Works

Results (13087)

Molecular characterization of clinical response and relapse in patients with IDH1-mutant newly diagnosed acute myeloid leukemia treated with ivosidenib and azacitidine

Meeting Abstract

Daigle, S. R.; Choe, S.; DiNardo, C. D.; Stein, A. S.; Stein, E. M.; Fathi, A. T.; Frankfurt, O.; Schuh, A. C.; Döhner, H.; Martinelli, G.; more...
Blood (2020)

Fulltext@MSK | Save

SY-1425, a potent and selective RARα agonist, in combination with azacitidine demonstrates a high complete response rate and a rapid onset of response in RARA-positive newly diagnosed unfit acute myeloid leukemia

Meeting Abstract

De Botton, S.; Cluzeau, T.; Vigil, C. E.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Liesveld, J. L.; Fenaux, P.; Braun, T.; Banos, A.; more...
Blood (2020)

Fulltext@MSK | Save

Biomarker driven umbrella trial of crenolanib in combination with ivosidenib, enasidenib, venetoclax, vyxeos and/or salvage chemotherapy in FLT3 mutant AML

Meeting Abstract

Daver, N.; Goldberg, A. D.; DiNardo, C. D.; Kadia, T. M.; Wang, E. S.; Stone, R. M.; Zhang, H.; Messahel, B.
Blood (2020)

Fulltext@MSK | Save

TCR repertoires in graft-versus-host-disease (GVHD)-target tissues reveals tissue specificity of the alloimmune response

Meeting Abstract

DeWolf, S.; Nichols, K.; Nguyen, C. L.; Giardina, P. A.; Slingerland, J. B.; Elias, H.; Kappangantula, R.; Baez, P.; Murali, R.; Hayashi, A.; more...
Blood (2020)

Fulltext@MSK | Save

Phase 1 trial of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): Activity in CML chronic phase patients failing TKI therapies including ponatinib

Meeting Abstract

Cortes, J. E.; Saikia, T.; Kim, D. W.; Alvarado, Y.; Nicolini, F. E.; Khattry, N.; Rathnam, K.; Apperley, J.; Deininger, M. W.; de Lavallade, H.; more...
Blood (2020)

Fulltext@MSK | Save

HORIZON (OP-106) versus MAMMOTH: An indirect comparison of efficacy outcomes for patients with relapsed/refractory multiple myeloma refractory (RRMM) to anti-CD38 monoclonal antibody therapy treated with melflufen plus dexamethasone versus conventional agents

Meeting Abstract

Creixenti, J. B.; Mateos, M. V.; Oriol, A.; Larocca, A.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
Blood (2020)

Fulltext@MSK | Save

Revealing transcriptome deregulation upon genomic complexity in multiple myeloma

Meeting Abstract

Da Via, M. C.; Ziccheddu, B.; Dugo, M.; Lionetti, M.; Todoerti, K.; D'Agostino, M.; Neri, A.; Baldini, L.; Corradini, P.; Maura, F.; more...
Blood (2020)

Fulltext@MSK | Save

The Prosid study: Evaluating efficacy and safety of intravenous immunoglobulin (IVIG) 10% in primary infection prophylaxis in patients with chronic lymphocytic leukemia-study design

Meeting Abstract

Cornely, O.; Mato, A.; Robak, T.; Mellinghoff, S.; Lavrova, T.
Blood (2020)

Fulltext@MSK | Save

Outcome by mutation status and line of treatment in optic, a dose-ranging study of 3 starting doses of ponatinib in patients with CP-CML

Meeting Abstract

Cortes, J. E.; Apperley, J.; Hochhaus, A.; Mauro, M. J.; Rousselot, P.; Sacha, T.; Talpaz, M.; Chuah, C.; Lipton, J. H.; Deininger, M. W.; more...
Blood (2020)

Fulltext@MSK | Save

Asciminib, a first-in-class STAMP inhibitor, provides durable molecular response in patients (pts) with chronic myeloid leukemia (CML) harboring the T315I mutation: Primary efficacy and safety results from a phase 1 trial

Meeting Abstract

Cortes, J. E.; Hughes, T. P.; Mauro, M. J.; Hochhaus, A.; Rea, D.; Goh, Y. T.; Janssen, J.; Steegmann, J. L.; Heinrich, M. C.; Talpaz, M.; more...
Blood (2020)

Fulltext@MSK | Save